GEHC at a glance
GE HealthCare (GEHC, SEC CIK 1932393) filed its latest 10-K annual report on February 4, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), GE HealthCare (GEHC) reported revenue of $20.6 billion (up 4.8% from FY2024) and net income of $2.1 billion. Diluted EPS was $4.55.
- As of September 30, 2026, 44 institutional investment managers tracked by SignalX reported holding GE HealthCare (GEHC) shares worth $11.3 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $20.6B
- +4.8% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 44 funds
- $11.3B · −4 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: global healthcare solutions provider delivering advanced medical tech, diagnostics, AI, cloud, and software for personalized patient care
- New emphasis on AI-enabled software solutions upgradeable through equipment lifecycle, enhancing multi-site healthcare network operations
- Strategic shift post-January 2023 spin-off from General Electric, operating independently with focus on lean system Heartbeat and operational culture
- Workforce approx. 54,000 employees, with 9,700 sales and 8,900 engineers and field service professionals globally
- Noteworthy: operates 44 manufacturing/production facilities across 17 countries with global integrated supply chain ensuring resilience and regional compliance
Risk Factors
- US tariffs on global imports in 2025 materially reduced profitability and cash flows, with ongoing risk of additional tariffs impacting financial results
- Russia-Ukraine conflict and resulting US, EU sanctions increased costs and restricted supply to Russian customers, with uncertain license approvals from US authorities
- Supply chain disruptions and raw material shortages causing manufacturing delays, higher costs, and delivery impairments
- U.S. Librarian of Congress copyright exemption enabling third-party ISOs to access OEM repair software threatens service contracts and revenues
- Existing indebtedness and potential additional borrowings pose financial constraints and risks to business operations
Management Discussion & Analysis
- Revenue $20,625M, up 4.8% YoY; Product sales $13,661M (+4.5%, +$586M), Services $6,964M (+5.6%, +$368M)
- Operating income $2,763M (13.4% margin vs 13.3%), net income $2,084M (10.1% margin, flat YoY)
- Best segment: PDx revenues $2,900M (+15.6%, +$392M) with EBIT $872M (+11.4%); Worst segment: PCS revenues $3,086M (-1.2%, -$38M) with EBIT $209M (-39.6%)
- Cost inflation including tariffs increased product costs $671M; operating expenses down $95M due to lower R&D and SG&A; tariffs impacted Operating income by $245M and cash flows by $285M
- No explicit forward guidance; key risks: ongoing tariffs, geopolitical instability, China market pressures, and trade restrictions may materially impact future results
AI summary of the GEHC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- Significant carried-forward risks remain unchanged from the latest annual filing
Management Discussion & Analysis
- Q3 revenue $5,513M, up 7.2% YoY from $5,143M, organic growth 6.2%
- Operating margin 14.6% vs 12.7% YoY, net margin 11.1% vs 8.7%
- Best segment PDx: revenue $846M, up 13.0%; worst PCS: nine-month revenue $2,171M, down 4.0%
- Operating cash flow $1,365M through nine months, up from $937M; $2,293M acquisition spending
- Tariffs reduced Q3 operating income by $53M; management expects continued material impacts if tariffs persist at current levels
AI summary of the GEHC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Taha Kass-Hout resigning as Chief Science and Technology Officer
- Departure effective December 31, 2026
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Jeannette Bankes resigning as President and CEO, Patient Care Solutions
- Departure effective November 15, 2026
Item EX-99.1: Item EX-99.1
- Q3 revenue $5.5B, up 7.2%, with organic growth 6.2% across all segments
- Adjusted EBIT margin 16.6%, up 180 bps, while adjusted EPS rose 25.1% to $1.34
Item 2.02: Results of Operations and Financial Condition
- GE HealthCare announced third-quarter 2026 financial results on October 28, 2026
- Detailed results, guidance, and management commentary are contained in Exhibit 99 press release
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Pascal Desroches joins GE HealthCare’s Board effective January 4, 2027
- Audit Committee and Talent, Culture, and Compensation Committee appointments expand his governance responsibilities
Item 7.01: Regulation FD Disclosure
- Pascal Desroches appointed to GE HealthCare’s Board effective September 22, 2026
- Board composition change potentially relevant to governance, oversight and strategic direction
AI summaries of GEHC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GEHC
Don't miss the next GEHC filing
- Alerts as it files. A push when GEHC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GEHC, by share count.
- Ask anything. An AI agent that reads every GEHC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sandy Neal Joseph | A | Nov 16, 2026 | 2,589 | - |
| Sandy Neal Joseph | A | Nov 16, 2026 | 1,018 | - |
| Grogan William K | A | Sep 14, 2026 | 62,256 | - |
| Grogan William K | A | Sep 14, 2026 | 12,840 | - |
| Grogan William K | A | Sep 14, 2026 | 31,877 | - |
| Arduini Peter J | F | Sep 3, 2026 | 6,303 | $70.56 |
| Jimenez Frank R | F | Sep 3, 2026 | 1,480 | $70.56 |
| Holton Adam Y | F | Sep 3, 2026 | 673 | $70.56 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $19.7B | $20.6B |
| Gross Profit | $7.9B | $8.2B | $8.2B |
| Operating Income | $2.4B | $2.6B | $2.8B |
| Net Income | $1.6B | $2.0B | $2.1B |
| Gross Margin | - | 41.7% | 40.0% |
| Op. Margin | - | 13.3% | 13.4% |
| Net Margin | - | 10.1% | 10.1% |
| Balance Sheet | |||
| Total Assets | - | $33.1B | $36.9B |
| Equity | - | $8.4B | $10.4B |
| ROE | - | 23.6% | 20.1% |
| Per Share | |||
| EPS | $3.03 | $4.34 | $4.55 |
| Cash Flow | |||
| Operating CF | - | $2.0B | $2.0B |
Source: XBRL data in GE HealthCare (GEHC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate GEHC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 44 | $11.26B |
| Q2 2026 | 48 | $11.50B |
| Q1 2026 | 47 | $12.01B |
| Q4 2025 | 46 | $14.28B |
| Q3 2025 | 45 | $13.00B |
| Q2 2025 | 44 | $12.97B |
| Q1 2025 | 44 | $10.27B |
| Q4 2024 | 39 | $7.90B |
- Millennium Management+507.2K (+175%)
- AQR Capital Management+474.5K (+68%)
- Dimensional Fund Advisors+220.8K (+4%)
- Invesco Ltd+157.5K (+1%)
- State Street Corp+135.6K (+1%)
- JPMorgan Chase & Co−2.19M (-21%)
- Goldman Sachs Group−1.20M (-27%)
- Citadel Advisors LLC−622.3K (-26%)
- Vanguard Portfolio Management LLC−333.9K (-2%)
- Bank of America Corp−175.4K (-5%)
- FMR LLC (Fidelity)−3.16M
- D.E. Shaw & Co−418.1K
- Equitable Holdings Inc−22.7K
- PARK NATIONAL CORP /OH/−48
Source: 13F-HR filings on SEC EDGAR (aggregated from 357 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GEHC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 10-Q | Oct 28, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
Related Health Care companies
- BFLY · Butterfly Network, Inc.X-Ray Apparatus & Tubes & Related Irradiation Apparatus
- HOLX · HologicX-Ray Apparatus & Tubes & Related Irradiation Apparatus
- NNOX · Nano-X Imaging Ltd.X-Ray Apparatus & Tubes & Related Irradiation Apparatus
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
GEHC SEC filings: frequently asked questions
Which institutions hold GEHC stock?
As of September 30, 2026, the largest GE HealthCare (GEHC) holders among the 13F filers tracked by SignalX were BlackRock ($2.4 billion), Vanguard Capital Management LLC ($1.9 billion), State Street Corp ($1.4 billion), Vanguard Portfolio Management LLC ($1.3 billion), Invesco Ltd ($1.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was GEHC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), GE HealthCare (GEHC) reported revenue of $20.6 billion (up 4.8% from FY2024) and net income of $2.1 billion. Diluted EPS was $4.55. The figures come from the XBRL data in the 10-K.
What are the main risks in GEHC's latest 10-K?
In the 10-K filed February 4, 2026, GE HealthCare (GEHC) flagged: US tariffs on global imports in 2025 materially reduced profitability and cash flows, with ongoing risk of additional tariffs impacting financial results. Russia-Ukraine conflict and resulting US, EU sanctions increased costs and restricted supply to Russian customers, with uncertain license approvals from US authorities. (AI summary of the Risk Factors section.)
What did GEHC report in its latest 8-K?
GE HealthCare (GEHC) filed an 8-K on November 5, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Taha Kass-Hout resigning as Chief Science and Technology Officer.
What are the latest GEHC SEC filings?
GE HealthCare (GEHC) filed its latest 10-K annual report on February 4, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 18, 2026.
What is GEHC's SEC CIK number?
GE HealthCare (GEHC)'s SEC Central Index Key (CIK) is 1932393. EDGAR lists every GEHC filing under that number.
Ask anything about GEHC
The research agent reads GEHC's filings, financials, insider trades and 13F holders, then answers with sources.